Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects

Juxtaposed Ideas15.35K FollowersFollow5ShareSavePlay(16min)Comments(4)SummaryEli Lilly's GLP-1 portfolio outpaces Novo Nordisk's sluggish performance, supported by the former's superior tolerability, strategic distribution partnerships, expanding US market share, and accelerated revenue growth.LLY trades near historical P/E means of ~30x with a 3Y PEG of 1.13x, offering attractive long-term upside potential to $1,492.70 for patient investors amid ongoing consolidation.Combined with the planned capacity expansions and the promising FY2026 guidance, LLY offers rich upside potential upon Orforglipron's upcoming US FDA approval/commercial launch.NVO is downgraded to Hold, given the disappointing FY 2026 guidance despite the tailwinds from the oral Wegovy launch and their first mover advantage.Barring an acceleration in its adj. EPS growth prospects and/or the upward re-rating in its valuations, NVO presents a potential value trap thesis here. Alones Creative/iStock via Getty Images I previously compared Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) (NONOF) in August 2025, discussing how the prior compounding/regulatory headwinds had triggered their painful corrections, worsened byThis article was written byJuxtaposed Ideas15.35K FollowersFollowI am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.